Federal Reserve Chairman Kevin Warsh has rapidly changed the Fed's communication style and moved away from traditional forward guidance, emphasizing a broader set of financial conditions to guide policy decisions. While he supports additional interest rate hikes if inflation remains high, progress on shrinking the Fed's $6.7 trillion balance sheet is slow due to economic conditions and internal consensus. Warsh's approach marks a significant shift from previous chairs by focusing on market indicators like credit availability and commodity prices. The market currently expects further rate increases, reflecting ongoing concerns about inflation and economic growth.
Federal Reserve Chairman Kevin Warsh's regime change at the Fed is the subject, with Pluang's Financials-sector market data as context. As of Sep 25, 2026 17:12 WIB, 59 of 85 priced Financials-sector US stocks rose while 19 fell. Notable movers include BBVA at USD 28.07 with a 1-day change of -1.40%, GEMI at USD 5.72 with +1.24%, and RIOT at USD 23.77 with +1.24%.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
